Duphar Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 11-01-2025
- Paid Up Capital ₹ 0.10 M
as on 11-01-2025
- Company Age 15 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -29.65%
(FY 2022)
- Profit -49.37%
(FY 2022)
- Ebitda -47.14%
(FY 2022)
- Net Worth 4.28%
(FY 2022)
- Total Assets 12.42%
(FY 2022)
About Duphar Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Riteshkumar Thakkar and Sangeetaben Thakkar serve as directors at the Company.
- CIN/LLPIN
U24230GJ2009PTC056460
- Company No.
056460
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Mar 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Duphar Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Riteshkumar Thakkar  | Director | 31-Mar-2019 | Current |
| Sangeetaben Thakkar | Director | 24-Nov-2015 | Current |
Financial Performance of Duphar Lifesciences.
Duphar Lifesciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 29.65% decrease. The company also saw a substantial fall in profitability, with a 49.37% decrease in profit. The company's net worth moved up by a moderate rise of 4.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Duphar Lifesciences?
In 2022, Duphar Lifesciences had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rht Pharmaceuticals Private LimitedActive 12 years 1 monthRiteshkumar Thakkar and Sangeetaben Thakkar are mutual person
- Roussel Laboratories Private LimitedActive 16 years 11 months
Riteshkumar Thakkar and Sangeetaben Thakkar are mutual person
- Duphar Bioscience Private LimitedActive 13 years 6 months
Riteshkumar Thakkar and Sangeetaben Thakkar are mutual person
- Greatlee Pharmaceuticals Private LimitedActive 2 years 10 months
Riteshkumar Thakkar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Duphar Lifesciences?
Unlock and access historical data on people associated with Duphar Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Duphar Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Duphar Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
